JAK2 and myeloproliferative neoplasm: It is important to note that, because JAK2 V617F is present in 95% of patients with PV but only in approximately 50% of patients with ET or PMF, a negative JAK2 V617F study should not by itself preclude the diagnosis of an underlying MPN.